Vera Therapeutics, Inc. (VERA) Financial Statements
Free cash flow over the same period: -$339.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VERAVera Therapeutics, Inc.Follow VERA — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 22.5 | 69.0 | 78.2 | 126.2 | 215.3 | 261.9 | |
| Operating income | -34.4 | -90.9 | -102.0 | -167.2 | -315.5 | -415.8 | |
| Pre-tax income | -32.6 | -89.1 | -96.0 | -152.1 | -299.6 | — | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -32.6 | -89.1 | -96.0 | -152.1 | -299.6 | -401.9 | |
| Diluted EPS ($) | -2.43 | -3.35 | -2.25 | -2.75 | -4.66 | -5.86 | |
| Diluted shares (mn) | — | 26.6 | 42.7 | 55.3 | 64.2 | — |
USD millions · SEC XBRL
Vera Therapeutics, Inc. — questions
- What is Vera Therapeutics, Inc.'s net income?
- -$401.9M over the twelve months to 2026-06-30.
- What is Vera Therapeutics, Inc.'s free cash flow?
- -$339.2M over the twelve months to 2026-06-30.
- What are Vera Therapeutics, Inc.'s diluted earnings per share?
- $-5.86 over the twelve months to 2026-06-30.
Every figure on this page comes from Vera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.